David R Brittelli

This inventor holds 20 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents. Top assignees: Bayer Corporation, Cgi Pharmaceuticals, Inc., Bayer Pharmaceuticals Corporation. Active years: 1998-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David R Brittelli. Retrieved from https://idiyas.com/inventor/david-r-brittelli

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 1)

% Patents Active = 90.0

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 4.8

ph-index = 7

Forward Citations = 146(Granted Patents)

Company Filing History:

Cgi Pharmaceuticals, Inc.

patents

2 out of 71

Bayer Pharmaceuticals Corporation

Gilead Connecticut, Inc.

patents

6. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2013

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8426424 - Certain substituted amides, method of making, and method of use thereof (2013-04-23),

2. 8222421 - Certain substituted ureas, as modulators of kinase activity (2012-07-17),

3. 7947835 - Certain substituted amides, method of making, and method of use thereof (2011-05-24),

4. 7777040 - Certain substituted ureas, as modulators of kinase activity (2010-08-17),

5. 6911449 - Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids (2005-06-28),

6. 6762184 - Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids (2004-07-13),

7. 6541468 - Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer (2003-04-01),

8. 6500847 - Inhibition of matrix metalloproteases by substitued biaryl oxobutyric acids (2002-12-31),

9. 6353006 - Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents (2002-03-05),

10. 6288063 - Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors (2001-09-11),

11. 6225314 - Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids (2001-05-01),

12. 6166082 - Substituted 5-biarylpentanoic acids and derivatives as matrix (2000-12-26),

13. 6013646 - Indolocarbazole derivatives useful for the treatment of (2000-01-11),

14. 5932577 - Substituted oxobutyric acids as matrix metalloprotease inhibitors (1999-08-03),

15. 5925637 - Inhibition of matrix metalloproteases by substituted biaryl oxobutyric (1999-07-20),

Title: **David R Brittelli: Innovator in Pharmaceutical Chemistry**

Introduction

David R Brittelli, based in Branford, CT, is a renowned inventor with an impressive portfolio of 20 patents. His work primarily focuses on the development of pharmaceutical compounds aimed at treating diseases such as cancer. Brittelli’s inventions leverage intricate chemical formulas to address significant health issues, demonstrating his commitment to innovation in the field of medicinal chemistry.

Latest Patents

Among his latest contributions to science, Brittelli has developed several critical patents. One notable invention involves certain substituted amides that inhibit Bruton’s tyrosine kinase (Btk). This invention is particularly relevant for treating diseases responsive to Btk activity inhibition, including various forms of cancer. The patent outlines the compounds involved and their pharmaceutical compositions, which can be formulated with carriers, adjuvants, and excipients.

Another significant patent covers certain substituted ureas as modulators of kinase activity. The findings provide essential insights into treating patients with diseases that respond to angiogenic kinase modulation. This patent emphasizes the potential of these chemical entities in reducing symptoms associated with various cancers, including breast neoplasia and colon cancer. Both patents also include methods for detecting Btk and angiogenic kinases in samples, which may prove invaluable in clinical settings.

Career Highlights

Throughout his career, David R Brittelli has held positions at prominent companies, including Bayer Corporation and Cgi Pharmaceuticals, Inc. His experiences at these institutions have allowed him to cultivate a robust understanding of pharmaceutical development and innovation processes.

Collaborations

Brittelli has also collaborated with notable professionals in the field, such as Michael C VanZandt and Brian R Dixon. These partnerships have undoubtedly enriched his research endeavors and fostered an environment of scientific collaboration that drives innovation.

Conclusion

David R Brittelli stands out as a dedicated inventor whose contributions to pharmaceutical sciences have the potential to significantly impact patient care. With a solid foundation of patents, collaborations, and career experiences, he continues to play a pivotal role in advancing medicinal chemistry and addressing critical health challenges.

Profile summary based on public USPTO records.